We hypothesize that this difference in the cellular regulatory network will increase CD8+ T cells ability to infiltrate the tumor and maintain an anti-tumor state, impacting immunotherapy outcome when the proportion of CD137 high CD8 T cells is increased through the addition of an agonist therapy. The gene discussed is CD8A; the disease is neoplasm.